The Motley Fool Discussion Boards

Previous Page

Stocks I / Incyte Genomics


Subject:  INCY Date:  4/19/2017  9:09 AM
Author:  KathLamarre Number:  803 of 803

$INCY treatment of graft versus host disease granted orphan drug designation.
Price target lowered to $167 from $174 at Credit Suisse.
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us